These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

383 related items for PubMed ID: 17530620

  • 1. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
    Andrikovics H, Nahajevszky S, Szilvási A, Bors A, Adám E, Kozma A, Kajtár B, Barta A, Poros A, Tordai A.
    Hematol Oncol; 2007 Sep; 25(3):143-7. PubMed ID: 17530620
    [Abstract] [Full Text] [Related]

  • 2. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
    Li X, Yang J, Chen X, Liu J, Li H, Zheng J, He Y, Chen Z, Huang S.
    Cancer Genet Cytogenet; 2007 Jul 15; 176(2):166-8. PubMed ID: 17656262
    [Abstract] [Full Text] [Related]

  • 3. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G, Kurosu T, Arai A, Murakami N, Miura O.
    Cancer Genet Cytogenet; 2010 May 15; 199(1):56-61. PubMed ID: 20417871
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
    Bennour A, Beaufils N, Sennana H, Meddeb B, Saad A, Gabert J.
    J Clin Pathol; 2010 Aug 15; 63(8):737-40. PubMed ID: 20702476
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
    Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Larráyoz MJ, Lahortiga I, Andreu EJ, Márquez J, Beltrán de Heredia JM, Odero MD, Prósper F, Calasanz MJ.
    Cancer Genet Cytogenet; 2005 Jul 01; 160(1):22-6. PubMed ID: 15949566
    [Abstract] [Full Text] [Related]

  • 11. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK, Gruber FX, Wee L, Hovland R, Hjorth-Hansen H, Gedde Dahl T, Meyer P.
    Acta Haematol; 2009 Jul 01; 122(1):11-6. PubMed ID: 19641300
    [Abstract] [Full Text] [Related]

  • 12. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J.
    Cancer; 2008 Feb 15; 112(4):837-45. PubMed ID: 18085610
    [Abstract] [Full Text] [Related]

  • 13. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW.
    Clin Cancer Res; 2007 Oct 15; 13(20):6136-43. PubMed ID: 17947479
    [Abstract] [Full Text] [Related]

  • 14. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Qiu JY, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 15; 26(1):23-6. PubMed ID: 15946504
    [Abstract] [Full Text] [Related]

  • 15. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
    Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T.
    Clin Cancer Res; 2007 Dec 01; 13(23):7080-5. PubMed ID: 18056186
    [Abstract] [Full Text] [Related]

  • 16. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Clin Cancer Res; 2006 May 15; 12(10):3037-42. PubMed ID: 16707599
    [Abstract] [Full Text] [Related]

  • 17. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb 15; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 18. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome.
    Le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA.
    Am J Hematol; 2003 Aug 15; 73(4):249-55. PubMed ID: 12879428
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
    Gadzicki D, von Neuhoff N, Steinemann D, Just M, Büsche G, Kreipe H, Wilkens L, Schlegelberger B.
    Cancer Genet Cytogenet; 2005 Jun 15; 159(2):164-7. PubMed ID: 15899391
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.